ADMA BiologicsADMA -2.05%68 Graham Number is $4.99 as of Mar. 2026, which is 47% above its 10-year median of 3.40. GuruFocus rates ADMA with a GF Score™ of 68/100 and a GF Value™ of $18.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 252 Biotechnology companies, ADMA Biologics ranks worse than 50.4% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-07-12), the stock price of ADMA Biologics is $9.105. ADMA Biologics's graham number for the quarter that ended in Mar. 2026 was $4.99. Therefore, ADMA Biologics's Price to Graham Number ratio for today is 1.83.
The historical rank and industry rank for ADMA Biologics's Graham Number or its related term are showing as below:
ADMA'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.81 Med: 3.4 Max: 8.13
Current: 1.82
During the past 13 years, the highest Price to Graham Number ratio of ADMA Biologics was 8.13. The lowest was 1.81. And the median was 3.40.
ADMA's Price-to-Graham-Number is ranked worse than 50.4% of 252
companies
in the Biotechnology industry
Industry Median: 1.815
vs ADMA: 1.82
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
ADMA Biologics (NAS:ADMA) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
ADMA Biologics's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
9.105
/
4.99
=
1.83
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
ADMA Biologics Graham Number Related Terms
ADMA Biologics Graham Number Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs ZLAB, HRMY, STOK: Graham Number Comparison
For the Biotechnology subindustry, ADMA Biologics's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Price-to-Graham-Number vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a Graham Number of $4.99 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on ADMA Biologics and its competitors. This is 47% above median its historical median of 3.40. Over the past decade, ADMA Biologics' Graham Number has ranged from 1.81 to 8.13. According to the industry distribution chart, ADMA Biologics ranks #127 out of 252 companies in the Biotechnology industry, placing it in the top 50.4%.
Is ADMA Biologics' Graham Number too high?
ADMA Biologics' current Graham Number of $4.99 is 47% above median its 10-year median of 3.40. Over the past 10 years, this metric has ranged from a low of 1.81 to a high of 8.13. The Biotechnology industry median Graham Number is 1.82. ADMA Biologics' value of $4.99 is 174.9% above this industry median. Based on the distribution chart, ADMA Biologics ranks #127 out of 252 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ADMA Biologics has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Graham Number compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #127 out of 252 companies for Graham Number. This places ADMA Biologics in the lower half of its industry. The industry median Graham Number is 1.82. ADMA Biologics' value of $4.99 is 174.9% above this benchmark. Historically, ADMA Biologics' own Graham Number has ranged from 1.81 to 8.13 over the past decade. While the company's 10-year median is 3.40 vs. the industry median of 1.82, ADMA Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Biotechnology company?
The median Graham Number among Biotechnology companies is 1.82, based on 252 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Graham Number of $4.99 is 174.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Graham Number is 1.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Graham Number is $4.99, which is 47% above median its own 10-year median of 3.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.07, compared to a current price of $9.11 — trading 49.6% below its estimated fair value. The current Graham Number is $4.99, which is 47% above median its 10-year median of 3.40 and 174.9% above the Biotechnology industry median of 1.82. ADMA Biologics' overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Graham Number is $4.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.11 is trading 49.6% below its estimated GF Value™ of $18.07.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Graham Number: $4.99 (47% above median its 10-year median of 3.40)
GF Value™: $18.07 vs. price of $9.11 (49.6% below fair value)
Industry Position: 174.9% above the Biotechnology median (#127 of 252)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
68GF Score
Get the complete analysis for ADMA
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
